Catalyst Calendar

Mon, Aug 3, 2026

1 updates

8:00 AM

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at

Trial Start • Phase 1Trial initiation Mon, Aug 3, 2026, 8:00 AM EDTdesigntx.com

Tue, Jun 30, 2026

1 updates

DSGN

8:00 AM

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for

Trial Start • Phase 1Trial initiation Tue, Jun 30, 2026, 8:00 AM EDTdesigntx.com